worth a read...only a month old , recent enough https://leedejonesgable.com/wp-content/uploads/ONC_2023_03_06.pdf
Now: before anyone jumps all over this for either high or low.
Take in context.
RBC has a rating of $6 CDN with an $18 upside on partnership and/or phase 3 registration.
The range of rating are all over the place. None or which are lower than now.
All of which have a "buy" or "strong buy rating"
You see, boys & girls, if/when ONC gets approval, or partership. The whole game changes.
That will happen only after the Bracelt reults are released.
The up-coming ASCO presentation is expected to be the reveal of that...with a N.R. prior.
Could a buy-out happen before? anythiing is possible. My opinion , not likely.
ONC does not want to sell-out cheap & pahrma wont pay until they see the data.
The enclosed report gives lots to chew on.